This information was published on 2025-01-23T04:12:03 for IP Right Filed Published.
| Field | Value |
| (210) | 2516091 (IR 1834619) |
| (220) |
30 Sep 2024
|
| (300) |
US, 02 Apr 2024, 98479628
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances. |
| (540) | PELLMOFI |
| (550) | Word |
| (730) |
Constellation Pharmaceuticals, Inc.
|
Find out more about publications on the About page.